Chronic vagus nerve stimulation for drug-resistant epilepsy may influence fasting blood glucose concentration

Hongyun Liu

Chinese PLA General Hospital

Ping Zhan

Chinese PLA General Hospital

Fangang Meng

Beijing Tiantan Hospital Capital Medical University

Weidong Wang (✉ wang_weidong301@163.com)

Chinese PLA General Hospital

Research

Keywords: Blood glucose, Glycemic control, Vagus nerve stimulation, Autonomic nervous system, Glucose homeostasis

Posted Date: May 5th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-18513/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BioMedical Engineering OnLine on May 29th, 2020. See the published version at <https://doi.org/10.1186/s12938-020-00784-1>.

Abstract

Background Cervical vagus nerve stimulation (VNS) has been widely accepted as adjunctive therapy for drug-resistant epilepsy and major depression. Its effects on glycemic control in humans were however poorly understood. The aim of our study was to investigate the potential effects of VNS on fasting blood glucose (FBG) in patients with drug-resistant epilepsy.

Methods Patients with drug-resistant epilepsy who had received VNS implants at the same hospital were retrospectively studied. Effects on FBG, weight, body mass index and blood pressure were evaluated at 4, 8 and 12 months of follow-up.

Results 32 subjects (11 females/21 males, 19 ± 9 years, body mass index 22.2 ± 4.0 kg/m²) completed 12-month follow-up. At the 4 months, there were no significant changes in FBG concentrations from baseline to follow-up in both Sham-VNS (4.89 ± 0.54 vs. 4.56 ± 0.54 mmol/L, N=13, $p=0.101$) and VNS (4.80 ± 0.54 vs. 4.50 ± 0.56 mmol/L, N=19, $p=0.117$) groups. However, after 8 (4.90 ± 0.42 mmol/L, N=32, $p=0.001$) and 12 (4.86 ± 0.40 mmol/L, N=32, $p=0.002$) months of VNS, FBG levels significantly increased compared to baseline values (4.52 ± 0.54 mmol/L, N=32). Changes in FBG concentrations at both 8 ($R^2 = 0.502$, N=32, $p < 0.001$) and 12 ($R^2 = 0.572$, N=32, $p < 0.001$) months were negatively correlated with baseline FBG levels.

Conclusions Our study suggests that chronic cervical VNS elevates FBG levels with commonly used stimulation parameters in patients with epilepsy.

1 Background

Cervical vagus nerve stimulation (VNS) is widely accepted as adjunctive therapy for drug-resistant epilepsy and major depression that involves intermittent electrical stimulation of the left vagus nerve by a subcutaneously implanted programmable pulse generator. Since the first human implant of VNS therapy in 1988, more than 100,000 patients have been treated with VNS worldwide by the end of 2019^[1]. VNS is currently being explored as an alternative treatment for a wider range of diseases, including heart failure, chronic pain, stroke, inflammatory disorders, sepsis, obesity, and tinnitus^[2-8]. To date, however, the exact changes in blood glucose concentrations in patients undergoing VNS treatment remain largely unknown.

VNS was reported to have mixed influences on blood glucose levels in previous studies based on animal models. Early work in anesthetized dogs indicated that stimulation of the ventral vagus nerve resulted in no statistically significant change in plasma glucose level^[9]. Data from the insulin sensitivity study suggested that left cervical VNS yields an increase in blood glucose concentration with an increase in plasma insulin immunoreactivity in fed anesthetized rats^[10]. Meyers et al. also demonstrated that electrical stimulation of the intact or afferent cervical vagus nerve in rats causes a marked and sustained increase in blood glucose levels by suppression of pancreatic insulin secretion^[11]. In addition to confirming that chronic VNS raises blood glucose concentrations, a recent animal trial also revealed that cervical VNS impairs glucose tolerance^[12]. In contrast, data from a previous study showed that efferent

cervical VNS lowered blood glucose concentrations by activation of insulin secretion^[11], whereas analysis of the study conducted in obese pigs indicated that chronic bilateral vagal stimulation has the capacity to restore fasting glucose metabolism^[13]. Similarly, Yin et al. found VNS at low frequency resulted in a hypoglycemic effect in both normal and diabetic rats by enhancing vagal efferent activity^[14]. However, although the studies in animal models suggest that acute or chronic VNS have potential effects on glycemic control and glucose metabolism, far too little attention has been paid to the possible influences of chronic cervical VNS on fasting blood glucose (FBG) levels in humans.

To the best of our knowledge, nothing has been reported in the literature on cervical VNS on human FBG concentrations. The aim of the present study was to broaden the current insight on cervical VNS-induced influence on human blood glucose control. We retrospectively analyzed data from one center of a randomized, double-blind controlled trial to assess the efficacy and safety of 12 months of VNS in patients with drug-resistant epilepsy. The primary objective of this study was to assess the effects of chronic VNS on FBG levels across different follow-up time points. Moreover, we examined the association between FBG level and its changes at follow-up period and selected clinical variables such as body mass index (BMI), blood pressure and stimulation parameters.

2 Results

2.1 Participants and Demographics

The baseline demographic data, clinical characteristics, and preoperative diagnosis are given in Table S-1. The 32 patients included 21 men and 11 women ranging in age from 6 to 38 years at the time of VNS implantation. There were 28 patients whose seizures responded to VNS, with 17 patients having seizure reductions of at least 50% at the end of the 12 months follow-up period. After the double-blind period, 13 patients in the sham-VNS group also started receiving VNS treatment. A total of 5 (3 of them were from the VNS group, and the other 2 were from the sham-VNS group) of the 32 patients became seizure-free after the 12-month VNS treatment with no serious adverse events reported in the study population.

2.2 Effects of VNS on FBG concentration

Demographic data and clinical factors of the VNS group and the sham-VNS control group are presented in Table S-2. At baseline, there were no significant differences in gender distribution, age, AED regimens and seizure characteristics between the two groups. At the 4-month double-blinded follow-up period, FBG levels significantly increased in the overall study population (N=32) compared to baseline (4.83 ± 0.53 mmol/L vs. 4.52 ± 0.54 mmol/L, $p=0.026$). However, this overall change in FBG concentration was weakened when considering the VNS (N=19) and sham-VNS (N=13) groups separately. As shown in Figure 1, a comparison of the VNS and sham-VNS groups indicated no significant difference in FBG concentration (4.50 ± 0.56 mmol/L vs. 4.56 ± 0.54 mmol/L, $p=0.969$) between groups over the course of the double-blinded period. In addition, the FBG levels at 4 months follow-up were not significantly different

from baseline values in both groups (VNS: 4.80 ± 0.54 mmol/L vs. 4.50 ± 0.56 mmol/L, $p=0.101$; sham-VNS: 4.89 ± 0.54 mmol/L vs. 4.56 ± 0.54 mmol/L, $p=0.117$).

There were no significant differences in FBG levels between the VNS and sham-VNS control groups at 8 months (4.87 ± 0.48 mmol/L vs. 4.94 ± 0.33 mmol/L, $p=0.715$) and 12 months (4.90 ± 0.42 mmol/L vs. 4.79 ± 0.38 mmol/L, $p=0.477$) follow-up. As shown in Figure 2, FBG levels significantly increased in the 32 subjects for both 8-month (4.90 ± 0.42 mmol/L vs. 4.52 ± 0.54 mmol/L, $p=0.001$) and 12-month (4.86 ± 0.40 mmol/L vs. 4.52 ± 0.54 mmol/L, $p=0.002$) visits compared to baseline values. Specifically, both the VNS (4.87 ± 0.48 mmol/L vs. 4.50 ± 0.56 mmol/L, $p=0.018$) and sham-VNS (4.94 ± 0.33 mmol/L vs. 4.56 ± 0.54 mmol/L, $p=0.021$) groups had a significant increase in FBG concentrations at 8 months as compared to baseline. At 12 months, patients in the VNS group had a significant increase in FBG level as compared to baseline (4.90 ± 0.42 mmol/L vs. 4.50 ± 0.56 mmol/L, $p=0.002$), whereas patients in the sham-VNS group did not (4.79 ± 0.38 mmol/L vs. 4.56 ± 0.54 mmol/L, $p=0.221$).

2.3 Effects of VNS on Body Weight, BMI, and Blood Pressure

There were no significant differences in body weight, BMI, systolic blood pressure and diastolic blood pressure between the VNS and sham-VNS groups. Body weight, BMI and blood pressure at various clinical visits following VNS device implantation are shown in Table 1 and Table 2. At 4 months, there were no significant changes in body weight, BMI, systolic and diastolic blood pressure compared to baseline. No significant differences were observed for changes in systolic and diastolic blood pressure at 8 and 12 months follow-up. For the overall study subjects, there was an increase in BMI at 12-month (23.1 ± 4.3 kg/m² vs. 22.2 ± 4.0 kg/m², $p=0.009$) follow-up compared to baseline. Moreover, measures of body weight increased both over the course of 8 (59.9 ± 20.4 kg vs. 57.8 ± 20.4 kg, $p=0.001$) and 12 (61.7 ± 19.9 kg vs. 57.8 ± 20.4 kg, $p=0.006$) months in the study population compared to the pre-operative weight. Weight gains at 8 and 12 months were 2.1 ± 0.7 kg and 3.9 ± 0.7 kg, respectively.

2.4 Effects of age, BMI, Baseline FBG Levels, and Stimulation Amplitude

Multiple linear regression analysis showed that age at VNS implantation, baseline fasting glucose concentrations, and BMI at corresponding visits were not identified as significant predictors for FBG levels at various follow-up time points (Figure 3). For the overall study population, higher stimulation amplitude was associated with higher FBG levels at 8 ($p=0.040$) and 12 ($p=0.001$) months follow-up. Partial correlation also demonstrated that there were moderate, positive partial correlation between FBG levels and stimulation amplitude whilst controlling for BMI (31.1 ± 9.1 years) at 8 ($r=0.364$, $N=32$, $p=0.044$) and 12 ($r=0.544$, $N=32$, $p=0.002$) months of follow-up. As shown in Figure 4, multiple linear regression results indicated that changes in FBG values ($p<0.001$). In addition, age at baseline, BMI and stimulation amplitude at the corresponding follow-up period had no significant effects on changes in FBG concentrations from baseline to various follow-up visits.

3 Discussion

The present retrospective study demonstrated for the first time that chronic cervical VNS may have the potential ability to increase FBG in patients with drug-resistant epilepsy. However, the elevated FBG levels which evolved the course of 12 months is still within the normal range. The changes in FBG concentrations did not associate with age at baseline, BMI and stimulation amplitude at the corresponding follow-up period. Additionally, results showed that 12-month of chronic cervical VNS significantly increased body weight of patients with drug-resistant epilepsy without obviously affecting their systolic and diastolic blood pressure.

The autonomic nervous system (ANS), which composed of sympathetic and parasympathetic (vagal) branches is crucial in regulating glucose metabolism^[17-20]. Furthermore, the central nervous system (CNS) maintains glucose homeostasis through ANS mediated control of the metabolically relevant organs including pancreas, liver, gut, skeletal muscle, and brown and white adipose tissues^[21,22]. As a fast-growing neuromodulation technology in the past 30 years, cervical VNS has been proven to be a useful adjunctive therapy across a number of diseases by stimulating the mixed autonomic vagus nerve in the neck. Since the vagus nerve provides an extensive efferent and afferent network of innervation for the organs and glands related to glucose metabolism, whether cervical VNS will affect the patient's blood glucose level in the treatment of drug-refractory epilepsy is a question worth studying. The most important observation of the present study shows that electrical stimulation of the left cervical vagus nerve, which provides a way to affect the autonomic function and regulate the autonomic tone, induces an elevation in FBG levels in patients with drug-resistant epilepsy. In fact, chronic VNS yields an increase in FBG concentrations in most patients and, consequently, the overall effect of VNS could be noticed. This finding is inconsistent with the results of a previous similar retrospective study, in which the conclusion that chronic cervical VNS in patients with epilepsy is unlikely to increase blood glucose levels or induce glucose intolerance with frequently used stimulation parameters^[23]. Nonetheless, results of the previous study varied widely, and further analysis suggests that stimulation on times longer than 25 sec appears to be related to elevation in blood glucose levels, especially if the stimulation off time is shorter than 200 sec. In our study, the stimulation on times for all patients was 30 sec, and the corresponding results seem to confirm the previous concern that chronic cervical VNS increases blood glucose concentrations to a certain extent. Recently, different VNS methods including different stimulation modes and stimulation locations, have been developed and applied to the study of glycemic control in humans. Stimulation mode varied from invasive to non-invasive; stimulation locations include cervical vagus nerve, subdiaphragmatic vagus nerve, and auricular vagus nerve. A pilot study in subjects with impaired glucose tolerance demonstrated transcutaneous auricular VNS (taVNS) significantly reduced two-hour glucose tolerance, which suggests that taVNS may be used as a preventive treatment for pre-diabetes^[24]. Stimulating different locations by different stimulation modes (taVNS vs. cervical VNS) may activation of different nerve fibers, and therefore have disparate potential effects on glucose metabolism. In a series of studies focusing on electrical stimulation of anterior and posterior intra-abdominal vagal trunks for obese subjects with type 2 diabetes mellitus, vagus nerve blocking significantly decreased glycosylated hemoglobin (HbA1C), and the beneficial effect is sustained at two-year follow-up period^[25-27]. However, in a prospective pilot vagus nerve blockade study on 7 non-diabetic obese subjects, electrical stimulation of

intra-abdominal vagal trunks showed no obvious beneficial effect on glucose metabolism, insulin secretion and action, or gastric emptying^[28]. Combining the results of the above studies, we speculate that whether VNS affects blood glucose metabolism may have a potential relationship with the subject's baseline blood glucose levels. In addition to the differences in stimulation mode, stimulation locations and specific stimulation parameters, the research subjects of the present study are different from those previous related studies. The non-diabetic epileptic patients in our study experienced an elevation in FBG levels after 12-month of VNS treatment. Furthermore, long-term increase in FBG concentrations is negatively associated with baseline FBG concentrations, which confirms our speculation and suggests that the effects of VNS on glycemic control are not a simple binary response process.

Our clinical observations remain inconsistent with experimental work demonstrating the effects of VNS on glycemic control in animal models. Continuous vagal stimulation was accompanied by a rise in blood glucose concentration were reported in anesthetized dogs^[29,30]. The data from another early observational study showed that VNS in the dogs produces a moderate increase of glucagon secretion and subsequently increases the arterial glucose levels^[31]. It is inferred that the effects of VNS on both the glucagon and insulin are mediated by ganglionic, nicotinic transmission. In a prandial insulin sensitivity study, VNS on fed rats caused an immediate increase in blood glucose levels, whereas a decrease in blood glucose level was observed after atropine administration^[10]. However, cervical VNS had no significant effects on blood glucose levels and plasma insulin in fasted rats. In Zucker diabetic fatty rats, taVNS reduced the glucose concentration to a normal level in seven days and effectively maintained the normal glycemic and plasma HbA1c levels when applied for five consecutive weeks^[32]. Importantly, the antidiabetic effect of taVNS is related to the triggering of tidal secretion of melatonin. Given the vagus nerve consists of about 80% sensory afferent and 20% motor efferent fibers^[33,34], Meyers et al. demonstrated that selective afferent cervical VNS induces a marked and sustained increase in blood glucose level in anesthetized rats, while selective efferent cervical VNS did increase blood glucose levels temporarily without inhibiting insulin secretion^[11]. Likewise, a recent study indicated that efferent vagal stimulation attenuates hyperglycemia in endotoxemia by inducing insulin in fasted mice^[35]. However, while combined afferent and efferent cervical VNS impaired glucose tolerance and inhibited glucose-induced insulin secretion in conscious rats^[12]. In contrast, cervical VNS of the intact vagus nerve at frequencies of 5 Hz and 14Hz reduces blood glucose in diabetic rats by enhancing vagal efferent activity and the release of glucagon-like peptide-1, and the effect of intermittent stimulation is more powerful than continuous stimulation^[14]. Current results demonstrated that cervical VNS increased FBG concentrations in non-diabetic subjects with commonly used stimulating parameters. These findings suggest that fibers within the cervical vagus nerve may differ in humans and animals, the specific vagus nerve fibers carry metabolic information both ascending to the CNS and descending to glycemic control organs may with different activation levels in animals and humans. While enticing, these data from animals and humans did not address the correspondence between stimulation of vagus nerve fiber subtypes and blood glucose regulation. To this end, specific electrodes and methodologies are needed for

a new paradigm of stimulation of target-specific vagus nerve fibers to achieve the purpose of glycemic control.

It has been reported that vagus nerve blocking is often associated with weight loss in obese patients^[25,26]. Studies focusing on patients with epilepsy or depression who underwent VNS implantation demonstrated that patients experienced significant weight loss after long-term treatment^[36,37]. Moreover, the weight loss induced by VNS is positively associated with baseline BMI^[37]. Similarly, data from animal models suggest that VNS actually induced weight loss but rather than preventing excess weight gain^[38]. In the present study, the change in weight is inconsistent with the findings of the above studies. Since the exact mechanisms by which cervical VNS influencing body metabolism and weight control remain incompletely understood, it is supposed that VNS may have a positive effect on appetite while relieving symptoms of epilepsy. In addition, the presence of seizures limits the activity of patients with epilepsy to a certain extent, thereby reducing energy metabolism and increasing in fat stores. Another source of possibility for the effect of VNS on weight is that stimulation of cervical vagus nerve disrupts vagal signaling both to and from the abdominal viscera related to gut motility and absorption. Future studies are warranted to elucidate the potential relationship between patient-specific VNS settings and weight control.

There are several limitations in the present study. First, as a retrospective study, it is impossible for us to do a very comprehensive analysis due to incomplete medical records. Due to the lack of hormonal data such as insulin, glucagon, and glucagon-like peptides-1, we cannot further explore the possible mechanism by which VNS can influence glycemic control. Second, the available data suggest that 12 months of cervical VNS raise FBG levels in epileptic patients. The magnitude of the glucose change is relatively small and may not be of clinical significance to patients with epilepsy, however this may not be true for diabetic patients. Although the FBG level is still within the normal range, we cannot answer the question if the FBG levels elevated following long-lasting chronic cervical VNS. Third, our study included patients receiving various AED, where the effect of AED on the glycemic control might be unpredictable. Finally, the findings in the current study are preliminary because they are based on a single-center, small-sample size study without no-treatment control group. Since there was no difference in FBG levels between the sham-VNS and VNS groups at 4 months, the increase in FPG from baseline to 4 months is also likely due to factor other than VNS, and it is also likely the cause for the additional increase in FPG at 8 and 12 months follow-up periods. Future multicenter, sizeable, and prospective study should be conducted to explore the interaction between chronic cervical VNS and glycemic control.

4 Conclusions

Our data demonstrate that electrical stimulation of vagus nerve at cervical level with commonly used parameters increases FBG concentrations in epileptic patients receiving VNS implantation. Moreover, the changes in FBG concentrations are negatively correlated with baseline FBG levels. While this is accompanied by the gains in weight, whether the elevation in FBG levels is causative physiology or

sequela is unclear. Whether patients with long-term cervical VNS treatment are at greater risk of developing glucose intolerance and diabetes remains to be elucidated.

5 Methods

5.1 Study Protocols

A randomized, double-blind controlled trial conducted in six centers to assess the efficacy and safety of 12 months of VNS in patients with drug-resistant epilepsy was retrospectively analyzed. The trial has been registered at clinicaltrials.gov protocol system (Clinical Trials Identifier: NCT02378792) and was updated in October 2016. Data from one center of the trial was selected for the present study to avoid the potential impact of VNS surgical procedures. At baseline period, subjects maintained a stable medication regimen for 4 weeks for seizure rate and basic clinical characteristics evaluation. Then, all participants were implanted with the VNS device (G111, PINS Medical, Ltd., Beijing, China) and randomized to either a VNS (n=19) or sham control (n=13) group. After the 2-week recovery period, the implanted pulse generators in the VNS group were turned on while those in the sham control group remained off. During the following 4-month double-blind period, the VNS group received patient-specific electrical stimulation and the sham control group received no stimulation. For the latter 8-month open-label period, subjects in the sham control group crossed over to receive personalized optimal stimulation. Both VNS and sham control groups were followed up to 12 months. Three months prior to the VNS surgery and during the 12-month follow-up period after the VNS treatment, the number and doses of the anti-epileptic drugs (AED) regimens, exercise and eating habits were kept unchanged, and the patients or their family members were asked to keep seizure diaries to determine the baseline and 12-month follow-up seizure frequency. This study was approved by the Institutional Review Committee of Beijing Tiantan Hospital Capital Medical University, and all subjects, or parents/guardians of the subjects, gave informed consent in written form including for the collection of their information and usage for research. The methods in the study were carried out in accordance with the approved guidelines.

5.2 Participants and Enrollment

The patients had undergone VNS surgery at the Beijing Tian Tan Hospital, Capital Medical University between August 13, 2014 and December 31, 2014 and had finished their 12-month follow-up evaluation were included in the study. All patients underwent complete presurgical evaluations and neuropsychological assessments as part of their diagnoses to ascertain that their drug-resistant epilepsy was not suitable for traditional epileptic craniotomy surgery^[15,16]. Key inclusion criteria included individuals who (1) were 6-60 years old, (2) had tried at least two appropriate AED tested to tolerance or to blood levels at the upper end of the target range of which at least 2 had been tolerated at the normal dose, (3) had at least 7 seizures per month, (4) were in good health except for epilepsy, (5) with a minimum mental state examination (MMSE) score ≥ 18 (no severe cognitive impairment). Key exclusion criteria included (1) the results of medical imaging examination indicating that the epilepsy was caused by intracranial space-occupying lesions, (2) tumors, cardiopulmonary anomalies, diabetes, progressive

neurological diseases, asthma, mental disease, or any other known disease that may have affected the autonomic nervous system function, (3) alcohol addiction, smoking, and sleep-related breathing disorders, (4) a history of medication that may have impacted the autonomic function and blood glucose levels.

5.3 VNS Treatment

The VNS system (G111, PINS Medical, Ltd., Beijing, China) was implanted under general anesthesia by an otolaryngologist. Spiral electrodes were placed around the left vagus nerve and connected to the programmable pulse generator subcutaneously. After VNS implantation, participants were randomized to either the VNS group (n = 19) or to the sham-VNS control group (n = 13). For the VNS group, pulse generator was turned on 2 weeks after implantation with initial settings being a current amplitude of 0.2 mA, frequency of 30 Hz, pulse width of 500 μ s, stimulus on time of 30 seconds, and stimulus off time 5 minutes. Adjustments were made at intervals of about 2 weeks until the stimulation reached 1.0 mA. This was followed by 1-month intervals for the first 4 months and then preceded by 4-month intervals. At each follow-up visit, the output current was progressively increased by 0.2-0.3 mA until 1) the seizures were reduced by more than 50%, 2) the patient no longer tolerated the treatment, or 3) the current reached a maximum of 3.5 mA. In the sham-VNS control group, the output current was increased temporarily during each visit and switched off at the end of the visit. At the beginning of the open-label phase, the stimulation parameters of the sham-VNS control group were adjusted according to the procedure and parameters of the VNS group.

5.4 Evaluations and Outcome Measurements

The primary outcome measure of the present study is the FBG concentrations in the morning measured at baseline, 4 months, 8 months and 12 months. All FBG concentrations were measured by the glucose oxidase method. Secondary outcomes include body weight, BMI, and blood pressure assessed at baseline and all clinic visits within the 12-month follow-up period. In addition, demographic data, seizure type, epilepsy duration, etiology, age at VNS surgery, seizure frequency, number of AED used, total dose of AED per day, presurgical MRI or PET findings, ictal scalp video-EEG characteristic, preoperative ECG recordings at baseline and the changes in severity of epilepsy at all clinical visits were observed.

5.5 Statistical Analysis

Data are presented as mean $\pm$ standard deviation (SD) for continuous variables. Gaussian distribution and homogeneity of variance tests were applied to determine the distribution and homoscedasticity of sample data. As a result of the non-normal distribution and heterogeneity of variance of some sample data, a Mann-Whitney U test was applied to compare the differences between VNS and sham-VNS groups. The Wilcoxon signed-rank test was used to compare the clinical variables of the 32 patients with drug-resistant epilepsy for the baseline and 4, 8, and 12 months after VNS treatment. For single predictive variable analysis using qualitative or categorical variables, Fisher's exact tests were applied for comparison of the equality of proportions between the VNS and sham-VNS control groups. Multiple linear

regression analyses were also employed to identify independent clinical factors related to fasting glucose levels and /or its changes at 4, 8 and 12 months follow-up. The goodness of fit of the test and reference regression line was quantified by the coefficient of determination R^2 . Partial correlation was applied to strengthen the relationship between FBG and stimulation amplitude whilst controlling for the effect of BMI. Statistical analyses were performed using SPSS version 20 software package (SPSS, Chicago, Ill, USA). All the p values were adjusted using the false discovery rate (FDR) method and a value of $p < 0.05$ was considered to indicate statistical significance.

Abbreviations

VNS: vagus nerve stimulation **BMI**: body mass index **AED**: anti-epileptic drugs **MMSE**: minimum mental state examination **SD**: standard deviation **FDR**: false discovery rate **ANS**: autonomic nervous system **CNS**: central nervous system **taVNS**: transcutaneous auricular vagus nerve stimulation **HbA1C**: glycosylated hemoglobin

Declarations

Ethics approval and consent to participate

The Institutional Review Committee of Beijing Tiantan Hospital Capital Medical University approved the collection of medical records and usage for research.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding authors F.M. (email: mengfangang@126.com) or W.W. (email: wang_weidong301@163.com) on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the National Key Technology R&D Program, Ministry of Science and Technology (2016YFC1305703, 2013BAI03B03, 2015BAI01B08), Chinese PLA General Hospital (2016-tm-042), and the National Natural Science Foundation of China (61372047, 61701540).

Authors' contributions

HYL: responsible for the design and implementation of research, and wrote the main body of the manuscript. PZ: responsible for clinical data analysis. FGM: diagnosed and carried out the VNS surgery for the patients with drug-resistant epilepsy. WDW supervised the work. All authors read and approved the final manuscript.

Acknowledgments

The authors gratefully acknowledge the services of Professor Fangang Meng in Beijing Tian Tan Hospital for his valuable work in diagnosing patients with drug-resistant epilepsy. We also thank Beijing Tian Tan Hospital for their medical technological support.

Disclosures

Not applicable.

References

- [1] Yang J, Phi JH. The present and future of vagus nerve stimulation. *J Korean Neurosurg Soc.* 2019;62 (3):344–352.
- [2] Zhang Y, Popovic ZB, Bibevski S, Fakhry I, Sica DA, Van Wagoner DR, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high–rate pacing model. *Circ Heart Fail.* 2009;2(6):692–699.
- [3] Lange G, Janal MN, Maniker A, Fitzgibbons J, Fobler M, Cook D, et al. Safety and efficacy of vagus nerve stimulation in fibromyalgia: a phase I/II proof of concept trial. *Pain Med.* 2011;12(9):1406–1413.
- [4] Chapleau MW, Rotella DL, Reho JJ, Rahmouni K, Stauss HM. Chronic vagal nerve stimulation prevents high–salt diet–induced endothelial dysfunction and aortic stiffening in stroke–prone spontaneously hypertensive rats. *Am J Physiol Heart Circ Physiol.* 2016;311(1):276–285.

- [5] Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature*. 2000;405(6785):458–462.
- [6] Kessler W, Diedrich S, Menges P, Ebker T, Nielson M, Partecke LI, et al. The role of the vagus nerve: modulation of the inflammatory reaction in murine polymicrobial sepsis. *Mediators Inflamm*. 2012;2012:467620.
- [7] Ikramuddin S, Blackstone RP, Brancatisano A, Toouli J, Shah SN, Wolfe BM, et al. Effect of reversible intermittent intra–abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. *JAMA*. 2014;312(9):915–922.
- [8] Tyler R, Cacace A, Stocking C, Tarver B, Engineer N, Martin J, et al. Vagus nerve stimulation paired with tones for the treatment of tinnitus: a prospective randomized double–blind controlled pilot study in humans. *Sci Rep*. 2017;7(1):11960.
- [9] Kaneto A, Miki E, Kosaka K. Effects of vagal stimulation on glucagon and insulin secretion. *Endocrinology*. 1974;95(4):1005–1010.
- [10] Peitl B, Döbrönte R, Németh J, Mezey G, Kovács P, Paragh G, et al. The prandial insulin sensitivity–modifying effect of vagal stimulation in rats. *Metabolism*. 2005;54(5):579–583.
- [11] Meyers EE, Kronemberger A, Lira V, Rahmouni K, Stauss HM. Contrasting effects of afferent and efferent vagal nerve stimulation on insulin secretion and blood glucose regulation. *Physiol Rep*. 2016;4(4):e12718.
- [12] Stauss HM, Stangl H, Clark KC, Kwitek AE, Lira VA. Cervical vagal nerve stimulation impairs glucose tolerance and suppresses insulin release in conscious rats. *Physiol Rep*. 2018;6(24):e13953.
- [13] Malbert CH, Picq C, Divoux JL, Henry C, Horowitz M. Obesity–associated alterations in glucose metabolism are reversed by chronic bilateral stimulation of the abdominal vagus nerve. *Diabetes*. 2017;66(4):848–857.
- [14] Yin JY, Ji F, Gharibani P, Chen J. Vagal nerve stimulation for glycemic control in a rodent model of type 2 diabetes. *Obes Surg*. 2019;29:2869–2877.
- [15] Moshé SL, Perucca E, Ryvlin R, Tomson T. Epilepsy: new advances. *Lancet* 2015;385:884–898.
- [16] Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen HW, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010;51:1069–1077.
- [17] Cannon WB. Organization for physiological homeostasis. *Physiol Rev*. 1929;9:399–431.
- [18] Buijs RM. The autonomic nervous system: a balancing act. *Handb Clin Neurol*. 2013;117:1–11.

- [19] Kumar VM. Neural regulation of glucose homeostasis. *Indian J Physiol Pharmacol*. 1999;43(4):415–424.
- [20] Carnagarin R, Matthews VB, Herat LY, Ho JK, Schlaich MP. Autonomic regulation of glucose homeostasis: a specific role for sympathetic nervous system activation. *Curr Diab Rep*. 2018;18(11):107.
- [21] Arble DM, Sandoval DA. CNS control of glucose metabolism: response to environmental challenges. *Front Neurosci*. 2013;7:doi:10.3389/fnins.2013.00020.
- [22] Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. *Physiology*. 2009;24:159–170.
- [23] Stauss HM, Daman LM, Rohlf MM, Sainju RK. Effect of vagus nerve stimulation on blood glucose concentration in epilepsy patients – Importance of stimulation parameters. *Physiol Rep*. 2019;7(14):e14169.
- [24] Huang F, Dong J, Kong J, Wang H, Meng H, Spaeth RB, et al. Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study. *BMC Complement Altern Med*. 2014;14:203.
- [25] Shikora S, Toouli J, Herrera MF, Kulseng B, Zulewski H, Brancatisano R, et al. Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus. *J Obes*. 2013;2013:245683.
- [26] Shikora SA, Toouli J, Herrera MF, Kulseng B, Brancatisano R, Kow L, et al. Intermittent vagal nerve block for improvements in obesity, cardiovascular risk factors, and glycemic control in patients with type 2 diabetes mellitus: 2-year results of the VBLOC DM2 study. *Obes Surg*. 2016;26:1021–1028.
- [27] Apovian CM, Shah SN, Wolfe BM, Ikramuddin S, Miller CJ, Tweden KS, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. *Obes Surg*. 2017;27:169–176.
- [28] Sathananthan M, Ikramuddin S, Swain JM, Shah M, Piccinini F, Dalla Man C, et al. The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. *Diabetes Metab Syndr Obes*. 2014;7:305–312.
- [29] Frohman LA, Ezdinli EZ, Javid R. Effect of vagotomy and vagal stimulation on insulin secretion. *Diabetes*. 1967;16:443–448.
- [30] Kaneto A, Miki E, Kosaka K. Effects of vagal stimulation on glucagon and insulin secretion. *Endocrinology*. 1974;95:1005–1010.
- [31] Ahrén B, Taborsky GJ Jr. The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. *Endocrinology*. 1986;118(4):1551–1557.

- [32] Wang S, Zhai X, Li S, McCabe MF, WangX, Rong P. Transcutaneous vagus nerve stimulation induces tidal melatonin secretion and has an antidiabetic effect in Zucker fatty rats. PLoS ONE. 2015;10(4):e0124195.
- [33] Rutecki P. Anatomical, physiological, and theoretical basis for the antiepileptic effect of vagus nerve stimulation. *Epilepsia*. 1990;31(Suppl 2):S1–S6.
- [34] Foley JO, DuBois F. Quantitative studies of the vagus nerve in the cat. I. The ratio of sensory to motor fibers. *J comp Neurol*. 1937;67:49–97.
- [35] Joseph B, Shimojo G, Li ZF, Thompson-Bonilla MDR, Shah R, Kanashiro A, et al. Glucose activates vagal control of hyperglycemia and inflammation in fasted mice. *Sci Rep*. 2019;9:1012.
- [36] Burneo JG, Faught E, Knowlton R, Morawetz R, Kuzniecky R. Weight loss associated with vagus nerve stimulation. *Neurology*. 2002;59(3):463–464.
- [37] Pardo JV, Sheikh SA, Kuskowski MA, Surerus-Johnson C, Hagen MC, Lee JT, et al. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. *Int J Obes*. 2007;31:1756–1759.
- [38] Val-Laillet D, Biraben A, Randuineau G, Malbert CH. Chronic vagus nerve stimulation decreased weight gain, food consumption and sweet craving in adult obese minipigs. *Appetite*. 2010;55(2):245–252.

Tables

Variables	Sham-VNS, n=13		VNS, n=19		p1	p2	p3
	Baseline	4 months	Baseline	4 months			
Height (cm)	162±16	163±15	155±23	157±21	0.700	0.041	0.009
Body weight (kg)	60.9±20.4	61.1±19.2	55.6±20.8	57.1±21.0	0.282	0.685	0.065
BMI (kg/m ²)	22.3±3.9	22.2±3.7	22.2±4.2	22.3±4.3	1.000	0.814	0.199
Systolic blood pressure (mmHg)	116±21	114±13	115±14	115±12	0.788	0.666	0.896
Diastolic blood pressure (mmHg)	73±11	74±8	76±11	78±10	0.847	0.944	0.081

Table 1. Baseline and 4 months follow-up characteristics of the Sham-VNS and VNS groups. P values were provided for comparison as follows: (1) p1: Sham-VNS vs. VNS at baseline; (2) p2: Baseline vs. 4 months follow-up for Sham-VNS group; (3) p3: Baseline vs. 4 months follow-up for VNS group.

Variables	Baseline	8 months	12 months	p1	p2	p3
Height (cm)	158±20	160±18	159±18	0.003	0.011	0.432
Body weight (kg)	57.8±20.4	59.9±20.4	61.7±19.9	0.001	0.006	0.006
BMI (kg/m ²)	22.2±4.0	22.5±4.2	23.1±4.3	0.294	0.009	0.054
Systolic blood pressure (mmHg)	115±17	111±11	113±12	0.094	0.318	0.288
Diastolic blood pressure (mmHg)	75±11	73±11	75±9	0.436	0.658	0.260
Amplitude (mA)	-	1.3±0.5	1.5±0.4	-	-	<0.001
Pulse width (µs)	-	500±0	500±0	-	-	1.000
Frequency (Hz)	-	30±0	30±0	-	-	1.000
On time (s)	-	30±0	30±0	-	-	1.000
Off time (min)	-	5±0	5±0	-	-	1.000

Table 2. Characteristics and VNS settings of the 32 patients with epilepsy at baseline, 8 months and 12 months follow-up. P values were provided for comparison as follows: (1) p1: after 8-month VNS vs. baseline; (2) p2: after 12-month VNS vs. baseline; (3) p3: after 12-month VNS vs. after 8-month VNS for all the study subjects.

Patient ID	Gender	Age (year)	Number of AEDs	AEDs and daily dose (mg)	Ictal scalp EEG characteristics	Seizure types	Etiology
P1	M	19	3	CBZ(900), VPA(1000), PHT(450)	Bilateral temporal abnormalities	GS, FS	Cryptogenic
P2	M	11	3	VPA(1000), CBZ(600), TPM(50)	Left parietal, occipital, temporal focus	FS	Symptomatic (left occipital lobe atrophy)
P3	M	7	4	TPM(12.5), VPA(500), CZP(1.25), LTG(100)	Bilateral frontal, temporal focus	GS, FS	Cryptogenic
P4	M	19	1	LEV(1000)	Left temporal focus	FS	Cryptogenic
P5	F	27	4	LEV(1500), PHB(90), LTG(200), VPA(1000)	Bilateral frontal, temporal focus	GS, FS	Symptomatic (postencephalitis)
P6	M	22	2	OXCZB(900), LEV(1000)	Bilateral frontal, temporal focus	GS, FS	Symptomatic(white matter myelination)
P7	M	33	1	CBZ(600)	Bilateral temporal abnormalities	GS, FS	Symptomatic (right hippocampal atrophy)
P8	M	21	7	MGVPA(500), DZP(20), PHT(300), OXCZB(900), LTG(150), TCM(2800)	Bilateral frontal, temporal focus	GS	Cryptogenic
P9	F	24	3	LTG(200), LEV(2000), OXCZB(1500)	Bilateral temporal abnormalities	GS	Symptomatic (encephalomalacia)
P10	F	28	2	VPA(1000), LTG(150)	Bilateral temporal, occipital focus	GS	Cryptogenic
P11	F	19	1	VPA(1000)	Left frontal, parietal; Right temporal, parietal focus	GS	Symptomatic (encephalomalacia & craniocerebral trauma)
P12	M	27	2	PHB(180), CBZ(1800)	Non-specific EEG abnormalities	GS	Cryptogenic
P13	F	25	1	VPA(400)	Left occipital, bilateral temporal abnormalities	GS, FS	Symptomatic (right hippocampal atrophy)
P14	M	18	2	LEV(250), VPA(1000)	Right temporal abnormalities	GS, FS	Symptomatic (left hippocampal sclerosis)
P15	F	19	4	CBZ(1100), LEV(2000), PHB(45), LTG(150)	Bilateral frontal, parietal, temporal abnormalities	GS, FS	Symptomatic (postencephalitis)
P16	M	7	1	CBZ(400)	Left parietal focus	FS	Symptomatic (tuberous sclerosis)
P17	M	32	1	VPA(1500)	Non-specific EEG abnormalities	GS	Cryptogenic
P18	M	21	1	VPA(1500)	Right temporal focus	GS, FS	Symptomatic (encephalomalacia)
P19	M	38	2	CBZ(600), MGVPA(500)	Right temporal, bilateral frontal abnormalities	GS, FS	Symptomatic (postoperative glioma)
P20	F	21	1	CBZ(800)	Right parietal, temporal focus	FS	Cryptogenic
P21	M	31	2	MGVPA(1000), CPNCM(1000)	Right frontal, temporal abnormalities	GS, FS	Symptomatic (encephalomalacia)
P22	M	12	2	OXCZB(450), ZNS(300)	Non-specific EEG abnormalities	GS, FS	Symptomatic (heterotopias)
P23	M	25	2	CBZ(200), LTG(50)	Right frontal, parietal, temporal abnormalities	GS, FS	Symptomatic (pachygyria abnormality)
P24	M	10	3	LTG(62.5), LEV(1500), VPA(18)	Non-specific EEG abnormalities	FS	Cryptogenic
P25	F	7	3	LEV(750), VPA(500), TPM(150)	Bilateral temporal, Right parietal focus	GS	Symptomatic (encephalomalacia)
P26	F	11	2	LTG(250), OXCZB(450)	Non-specific EEG abnormalities	GS, FS	Cryptogenic
P27	F	10	4	LTG(50), CPNCM(600), PMT(250), MGVPA(500)	Left temporal abnormalities	FS	Symptomatic (left hippocampal abnormalities)

P28	M	15	2	CBZ(800), VPA(2000)	Left parietal, occipital, Bilateral temporal focus	GS, FS	Symptomatic (toxicosis)
P29	M	6	3	VPA(750), LTG(100), TPM(150)	Left frontal, parietal, temporal focus	FS	Symptomatic (focal cortical dysplasia)
P30	M	34	1	CBZ(1400)	Bilateral temporal, frontal abnormalities	GS, FS	Symptomatic (encephalomalacia & atrophy)
P31	F	10	3	OXCZB(375), ZNS(200), CZP(2)	Non-specific EEG abnormalities	FS	Cryptogenic
P32	M	7	4	OXCZB(900), TPM(150), PHB(60), CZP(3)	Non-specific EEG abnormalities	GS, FS	Cryptogenic

Table S-1. Clinical data of 32 patients with drug-resistant epilepsy. AEDs, antiepileptic drugs; VPA, valproate; LTG, lamotrigine; CBZ, carbamazepine; OXCZB, oxcarbazepine; LEV, levetiracetam; TPM, topiramate; PHB, phenobarbital; CZP, clonazepam; PHT, phenytoin; MGVPA, magnesium valproate; CPNCM, compound phenobarbital nitrazepam and chlorphenamine maleate; DZP, diazepam; ZNS, zonisamide; TCM: traditional Chinese medicine; PMT, primidone; GS, generalized seizure; FS, focal seizure.

Variables	Sham-VNS, n=13	VNS, n=19	Pooled, n=32	p
Demographic data				
Male/Female	9/4	12/7	21/11	1.000
Age (years)	19±8	20±10	19±9	0.817
AEDs information				
Number of AEDs	3±2	2±1	2±1	0.843
Daily dose (mg)	1547±1097	1453±845	1491±939	0.908
Seizure characteristics				
Epilepsy duration (years)	10±6	12±10	11±8	0.802
Seizures per month	79±137	124±233	106±198	0.155
FS	3 (23.1%)	5 (26.3%)	8 (25.0%)	1.000
GS	2 (15.4%)	5 (26.3%)	7 (21.9%)	0.671
GS+FS	8 (61.5%)	9 (47.4%)	17 (53.1%)	0.491
Etiology				
Symptomatic	7 (53.8%)	13 (68.4%)	20 (62.5%)	0.473
Cryptogenic	6 (46.2%)	6 (31.6%)	12 (37.5%)	0.473

Table S-2. Baseline clinical characteristics in the Sham-VNS and VNS groups. P values were provided for comparison between Sham-VNS and VNS groups at baseline. AED, antiepileptic drug; GS, generalized seizure; FS, focal seizure.

Figures

Figure 1

FBG concentration and its changes in sham-VNS and VNS groups. (A) FBG levels at baseline and at 4 months follow-up in the two groups. (B) Changes in FBG levels at 4 months follow-up in Sham-VNS and VNS groups. There were no significant differences in FBG levels between Sham-VNS and VNS groups. The FBG levels at 4 months follow-up were not significantly different from baseline values in both groups.

Figure 2

FBG concentration and its changes for the 32 patients receiving VNS treatment. (A) FBG levels at baseline, 8 and 12 months of long-term follow-up. (B) Changes in FBG levels at 8 and 12 months follow-up in the study subjects (N=32). Significant differences were noted in FBG concentrations for patients receiving VNS treatment at both 8 months (p=0.001) and 12 months (p=0.002) follow-up compared to baseline values.

Figure 3

Correlations between FBG levels at follow-up and BMI at follow-up, age, and FBG levels at baseline. The straight lines and the statistics (R^2 , N, p) is for the linear correlations and regressions between the two parameters with the study subjects according to the multiple linear regression analysis.

Figure 4

Effects of age and FBG levels at baseline, BMI and stimulation amplitude at corresponding follow-up period on changes in FBG levels from baseline to different follow-up periods. The straight lines and the statistics (R², N, p) are for the linear correlations between the two parameters with the study subjects according to the multiple linear regression analysis.